Status:
RECRUITING
The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger
Lead Sponsor:
Embryolab Fertility Clinic
Collaborating Sponsors:
ART Fertility Clinics LLC
Conditions:
Ovarian Stimulation
Human Chorionic Gonadotropin
Eligibility:
FEMALE
20-30 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to compare GnRH-agonist trigger with dual GnRH-agonist and HCG trigger in oocyte donors. The main questions it aims to answer are: * Maturation rate (Metaphase II/...
Detailed Description
Final oocyte maturation is a critical step in the process of the Assisted Reproductive Technology (ART) treatment and has a certain impact on oocyte yield and oocyte competency. There are three differ...
Eligibility Criteria
Inclusion
- BMI: 18 - 25
- AMH: 1-3ng/ml
- AFC: 15
- Peak E2 in previous ovarian stimulation cycle: \< 4000 pg/ml
- Ovarian response in first stimulation cycle: \< 20 follicles over 10mm in total, at time of triggering
- Peak E2 in study cycle: \< 4000 pg/ml
- Suboptimal response to trigger medication at first stimulation cycle
- Male age \< 50 years old with normospermia
Exclusion
- Oocyte donors which are at risk for development of ovarian hyperstimulation syndrome (OHSS)
Key Trial Info
Start Date :
November 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06142708
Start Date
November 1 2023
End Date
February 1 2026
Last Update
November 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Embryolab Fertility Clinic
Thessaloniki, Greece, 55133